E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Research Advances in Heart Failure A Compendium
TL;DR: Despite the spectacular advances of the past half century, cardiovascular disease is still the most common cause of death and disability in industrialized nations, and its prevalence is rising rapidly in developing nations.
Journal ArticleDOI
Rationale, design and baseline characteristics of the survival and ventricular enlargement trial
Lemuel A. Moyé,Lemuel A. Moyé,Lemuel A. Moyé,Marc A. Pfeffer,Marc A. Pfeffer,Marc A. Pfeffer,Eugene Braunwald,Eugene Braunwald,Eugene Braunwald +8 more
TL;DR: This observation suggests that measures used to prevent ventricular enlargement may improve postinfarction survival, and the Survival and Ventricular Enlargement (SAVE) trial is a randomized, double-blind, placebo-controlled clinical trial with the purpose of evaluating the effect of angiotensin-converting enzyme (ACE) inhibition on post infarction death and ventricular dilation.
Journal ArticleDOI
Ventricular septal defect and aortic regurgitation: Clinical, hemodynamic and surgical considerations
Journal ArticleDOI
Effects and mechanisms of action of dopamine on regional hemodynamics in the conscious dog
Journal ArticleDOI
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
Lawrence A. Leiter,Hwee Teoh,Eugene Braunwald,Ofri Mosenzon,Avivit Cahn,K M Prasanna Kumar,Alena Smahelova,Boaz Hirshberg,Christina Stahre,Robert Frederich,Francois Bonnici,Benjamin M. Scirica,Deepak L. Bhatt,Itamar Raz,Investigators +14 more
TL;DR: The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category.